18F-FDOPA PET/CT-Guided Radiofrequency Ablation of Liver Metastases from Neuroendocrine Tumours: Technical Note on a Preliminary Experience.

摘要: To review our preliminary experience with 6-l-18F-fluorodihydroxyphenylalanine (18F-FDOPA) PET/CT-guided radiofrequency ablation (RFA) of liver metastases from neuroendocrine tumours (NETs). Three patients (mean age 51.3 years; range 43–56) gastro-entero pancreatic NET (GEP-NET) underwent 18F-FDOPA RFA. Patients were referred oligometastatic hepatic-confined disease (1–6 metastases; <3 cm) on PET/CT; poor lesion visualisation US, CT, and MR; ongoing symptoms. Procedures performed in an interventional PET/CT scanner under general anaesthesia using a split-dose protocol. Lesion characteristics, procedural duration technical success (accurate probe placement post-procedural ablation-zone photopaenia), complications, patient operator dose, clinical outcomes evaluated. Thirteen size 11.4 mm, 8–16) treated three (two presented “carcinoid syndrome”). Technical was 100 % mean 173.3 min (range 90–210) no immediate complications. Mean dose 2844 mGy·cm 2104–3686). Operator radiographer doses acceptable other than the operator’s right hand first case (149 µSv); this normalised second case. There local tumour or extra-hepatic progression at mid-term follow-up 12.6 months; 6–20); however, two cases progressed new different sites. (n = 2) resolving carcinoid syndrome RFA appears technically feasible, safe, effective GEP-NETs low-burden hepatic metastases. Further prospective studies are required to elucidate its precise role tailored multimodality management GEP-NET